Afsaneh Barzi, MD
Medical Oncology · Los Angeles, CANPI 1265480412
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $78,648 of the $107,355 with a category attached, or 73.3%. 15 manufacturers reported payments, led by Bayer at 40.6% of the total. Reporting peaked in 2023 at $39,895 and has fallen 99.6% since, to $157 in 2025.
Across 88 payments — averaging $1219.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$44K
- Helsinn Therapeutics (U.S.), Inc.$21K
- AstraZeneca$17K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Daiichi Sankyo Inc.$6K
- Amgen$3K
- plus $5K from 9 others
Across 17 payments — averaging $94,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$922K
- Merck$619K
- Amgen$68K
What the payments were for
- Consulting fees$78,64873%
- Speaking & faculty fees$13,28012%
- Travel & lodging$14,06313%
- Food & beverage$1,3641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 28 | $43,573 |
| Helsinn Therapeutics (U.S.), Inc. | 15 | $21,072 |
| AstraZeneca | 14 | $16,695 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $11,715 |
| Daiichi Sankyo Inc. | 5 | $6,234 |
| Amgen | 2 | $2,758 |
| Astellas Pharma US Inc | 3 | $2,403 |
| Seagen Inc. | 1 | $1,375 |
| Astrazeneca UK Limited | 2 | $875 |
| Beigene USA, Inc. | 2 | $223 |
| Merck | 5 | $188 |
| Beone Medicines USA, Inc. | 1 | $157 |
| Ipsen Biopharmaceuticals, Inc | 1 | $50 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Dentsply Sirona Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,355 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoclopramide Hcl | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.